An Unexpected Post-ocrelizumab Improvement in Glycaemic Control in a Patient with Multiple Sclerosis

Abstract

Ocrelizumab, a novel member of disease-modifying therapies for multiple sclerosis (MS), is a humanised monoclonal antibody against the CD20 molecule on the surface of B cells. Reports on possible effects of this molecule in MS therapy have attracted a lot attention since its approval in 2017. The authors present a 31-year-old female patient who was diagnosed with MS in 2008, with a concomitant disease of Type 1 diabetes (T1D). The patient’s MS treatment included interferon-β1a and fingolimod prior to ocrelizumab initiation in 2019. In regard to the patient’s T1D course, they had poor glycaemic control despite regular follow-ups and strict treatment plans. Subsequent to the commencement of ocrelizumab therapy, a significant improvement was observed in their glycaemic control. The authors’ case study aims to raise motivation for further investigation and studies to evaluate this unexpected potential impact of ocrelizumab on T1D control.